“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A study of GDC-0449 before surgery for pancreatic cancer (HIPPoS)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
More about this trial
Researchers were trying to find out more about a new drug called GDC-0449. We know from laboratory research that it can block a type of chemical signalling between cells which may affect the growth of pancreatic cancer.
The aims of the study were to
- See the effect GDC-0449 has on pancreatic cancer and the surrounding healthy tissue
- Learn more about the side effects
Summary of results
This study closed early due to a lack of patients.
How to join a clinical trial
Professor D Tuveson
Cambridge University Hospitals NHS Foundation Trust
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)